Pascal Soriot, AstraZeneca CEO (via AP Images)
Why wait? The FDA stamps an ultra-fast OK on a HER2+ drug expected to create AstraZeneca's next blockbuster franchise
The FDA isn’t playing any waiting games when it comes to hustling up a quick OK for a breakthrough cancer drug.
In what has to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
